Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer.
We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features.
We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan-Meier curves. Cox proportional models were used for univariate and multivariate analyses.
We collected data from 66 patients with metastatic sarcomatoid renal cell carcinoma receiving cabozantinib as second-line (51%) or third-line (49%) therapy. The median progression-free survival from the start of cabozantinib was 7.59 months (95% confidence interval [CI] 5.75-17.49) and was longer in male patients (8.81 vs 5.95 months, p = 0.042) and in patients without bone metastases (7.59 vs 5.11 months, p = 0.010); the median overall survival was 9.11 months (95% CI 7.13-23.80). At the multivariate analysis, female sex (hazard ratio = 1.81; 95% CI 1.02-3.37, p = 0.046), bone metastases (hazard ratio = 2.62; 95% CI 1.34-5.10, p = 0.005), and International Metastatic Renal Cell Carcinoma Database Consortium criteria (hazard ratio = 3.04; 95% CI 1.54-5.99, p = 0.001) were significant predictors of worse overall survival.
Our data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options.
Targeted oncology. 2021 Aug 02 [Epub ahead of print]
Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli
Oncology Unit, Macerata Hospital, Macerata, Italy. ., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Department of Medical Oncology, Istituto Nazionale dei Tumori IRCCS, Milan, Italy., Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA., Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy., Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Department of Medical Oncology, Istituto Oncologico Veneto (IOV) IRCCS, Padua, Italy., U.O.C. Oncology, Azienda Ospedaliera Universitaria Integrata, University and Hospital Trust of Verona, Verona, Italy., Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy., Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Medical Oncology Department, Santa Chiara Hospital, Trento, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Oncology Unit, City Hospital, Faenza, Italy., Department of MedicalOncology, Hospital Ramón y Cajal, Madrid, Spain., Oncology Unit, Macerata Hospital, Macerata, Italy.